Discover 955 paid clinical trials in Salem, Oregon. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 955
Endolumenal Partial Myotomy for the Treatment of Esophageal Achalasia
for
Achalasia
Location: Portland OR
Sponsor: The Oregon Clinic
Sex: All
Age: 18 - 70+
Code: NCT01302288
Phase 2, Recruiting
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
for
Breast Cancer
Location: Portland OR, Eugene OR, Seattle WA, Mount Vernon WA,
Sponsor: Agendia
Sex: All
Age: 18+
Code: NCT03053193
Recruiting
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
for
Brain Metastases
Location: Portland OR, Vancouver, Great Falls MT, Calgary,
Sponsor: Canadian Cancer Trials Group
Sex: All
Age: 18+
Code: NCT03550391
Phase 3, Recruiting
Study of SGR-1505 in Mature B-Cell Neoplasms
for
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL,
Location: Portland OR, Seattle WA, Gilbert AZ, Dallas TX,
Sponsor: Schrödinger, Inc.
Sex: All
Age: 18+
Code: NCT05544019
Phase 1, Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
for
Ovarian Cancer
Location: Portland OR, Palo Alto CA, Salt Lake City UT,
Sponsor: Daiichi Sankyo
Sex: Female
Age: 18+
Code: NCT06819007
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation
for
Extracorporeal Membrane Oxygenation Complication,
Location: Portland OR
Sponsor: Legacy Health System
Sex: All
Age: 18+
Code: NCT03965208
Recruiting
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
for
Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Location: Portland OR, Bellevue WA, Oakland CA, Sherman Oaks CA,
Sponsor: Lighthouse Pharmaceuticals, Inc.
Sex: All
Age: 55 - 70+
Code: NCT06847321
Phase 2, Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
for
Non-small Cell Lung Cancer,
Location: Portland OR, Los Angeles CA, Santa Monica CA, Duarte CA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT05877599
Phase 1, Recruiting
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
for
Major Depressive Disorder
Location: Portland OR, Everett WA, Lafayette CA, Las Vegas NV,
Sponsor: Axsome Therapeutics, Inc.
Sex: All
Age: 18 - 65
Code: NCT06223880
Recruiting
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
for
Attention-deficit/Hyperactivity Disorder,
Location: Portland OR, Everett WA, Las Vegas NV, Austin TX,
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sex: All
Age: 18 - 65
Code: NCT07759154
Phase 3, Recruiting
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Sex: All
Age: 18 - 70+
Code: NCT07654361
Phase 3, Recruiting
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
for
Major Depressive Disorder (MDD)
Location: Portland OR, Everett WA, San Jose CA, Clinton UT,
Sponsor: Supernus Pharmaceuticals, Inc.
Sex: All
Age: 18 - 70
Code: NCT07226661
Phase 2, Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
for
Obesity or Overweight
Location: Portland OR, Surrey, Walnut Creek CA, Calgary,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07351045
Phase 3, Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2